Genetic Manipulation and Selection of Mouse Mesenchymal Stem Cells for Delivery of Therapeutic Factors In Vivo.

Genetic Manipulation and Selection of Mouse Mesenchymal Stem Cells for Delivery of Therapeutic Factors In Vivo. Methods Mol Biol. 2019;1940:143-155 Authors: Sakaguchi DS Abstract Bone marrow-derived mesenchymal stem cells (MSCs) hold great potential as an ex vivo cellular system for delivery of therapeutic proteins to the diseased or damaged central nervous system (CNS). This adult stem cell population has considerable translational potential for autologous transplantation due to lack of ethical concerns, accessibility, multipotent nature, and plasticity. Here we describe a methodology and outline a strategy using lentiviral vectors for producing lines of MSCs hypersecreting neurotrophic growth factors (e.g., brain-derived neurotrophic factor (BDNF) and/or glial cell line-derived neurotrophic factor (GDNF)) together with a reporter protein such as green fluorescent protein (GFP) that may be used for in vitro and in vivo neuroprotection bioassays. This approach provides exciting opportunities for basic research and proof-of-concept studies. PMID: 30788823 [PubMed - indexed for MEDLINE]
Source: Mol Biol Cell - Category: Molecular Biology Authors: Tags: Methods Mol Biol Source Type: research

Related Links:

Publication date: Available online 26 August 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Hyunkyung Park, Ja Min Byun, Youngil Koh, Sung-Soo Yoon, Hyejoo Park, Jayoun Lee, Sang-Jin Shin, Jeonghwan YoukAbstractBackgroundThe optimal the conditioning regimens for allogeneic hematopoietic stem-cell transplantation, especially for East Asian patients, remains unknown.Patients and MethodsWe collected and analyzed clinical and survival data of 4255 patients from the Korean National Health Insurance Claims Database.ResultsBetween 1562 myeloablative conditioning and 2693 nonmyeloablative conditioning groups, the ove...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 19 September 2019Source: Stem Cell ReportsAuthor(s): Denise Klatt, Erica Cheng, Friederike Philipp, Anton Selich, Julia Dahlke, Reinhold E. Schmidt, Juliane W. Schott, Hildegard Büning, Dirk Hoffmann, Adrian J. Thrasher, Axel SchambachSummaryMutations in the NADPH oxidase, which is crucial for the respiratory burst in phagocytes, result in chronic granulomatous disease (CGD). The only curative treatment option for CGD patients, who suffer from severe infections, is allogeneic bone marrow transplantation. Over 90% of patients with mutations in the p47phox subunit of the oxidase comple...
Source: Stem Cell Reports - Category: Stem Cells Source Type: research
Authors: Xia J, Minamino S, Kuwabara K, Arai S Abstract Stem cells are an undifferentiated cell population that has the ability to develop into many different cell types and also has the ability to repair damaged tissues in some cases. For a long time, the stem cell regenerative paradigm has been based on the assumption that progenitor cells play a critical role in tissue repair by means of their plasticity and differentiation potential. However, recent works suggest that the mechanism underlying the benefits of stem cell transplantation might relate to a paracrine modulatory effect rather than the replacement of a...
Source: BioScience Trends - Category: Biomedical Science Tags: Biosci Trends Source Type: research
Bone Marrow Transplantation, Published online: 20 September 2019; doi:10.1038/s41409-019-0650-xOutcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
Source: Bone Marrow Transplantation - Category: Hematology Authors: Source Type: research
The term hemolytic uremic syndrome (HUS) encompasses 3 different entities: typical HUS caused by a shiga toxin –producing Escherichia coli, primary atypical HUS (aHUS) resulting from the dysregulation of the complement alternative pathway, and secondary HUS caused by a variety of etiologies whose common characteristic is to induce diffuse endothelial damage leading to thrombotic microangiopathy (TMA). As s hown in Supplementary Table S1, the most common causes of secondary HUS are drugs, infections, autoimmune diseases, malignancies, and hematopoietic stem cell transplantation.
Source: Kidney International - Category: Urology & Nephrology Authors: Tags: Controversies in Nephrology Source Type: research
Severe sepsis (SS) in pediatric oncology patients is a leading cause of morbidity and mortality. We investigated the incidence of and risk factors for morbidity and mortality among children diagnosed with cancer from 2008 to 2012, and admitted with SS during the 3 years following cancer diagnosis. A total of 1,002 children with cancer were included, 8% of whom required pediatric intensive care unit (PICU) admission with SS. Death and/or multiple organ dysfunction syndrome occurred in 34 out of 99 PICU encounters (34%). Lactate level and history of stem-cell transplantation were significantly associated with the development...
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news
How much do you know about stem cell transplantation in multiple myeloma? Here's your chance to find out.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
Publication date: Available online 26 August 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Rafiye Ciftciler, Haluk Demiroglu, Ibrahim Celalettin Haznedaroglu, Nilgun Sayınalp, Salih Aksu, Osman Ozcebe, Hakan Goker, Muruvvet Seda Aydın, Yahya BuyukasıkAbstractBackgroundThe majority of patients with acute myeloid leukemia (AML) receive intensive induction chemotherapy for obtaining a complete remission (CR). Despite consolidation chemotherapy and advances in allogeneic hematopoietic stem cell transplantation, most of these patients finally relapse and die from AML. The aim of this study is to determine the ...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Abstract Advanced stage mycosis fungoides (MF) and Sézary syndrome (SS) account for ~30% of patients with cutaneous T-cell lymphomas (CTCL). The prognosis is poor with a median survival of 36 months.1 Treatments rarely result in durable remissions and recent management guidelines recommend allogeneic haematopoietic stem cell transplant (HSCT) for eligible patients as the best chance of improved survival. PMID: 31536644 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research
Bone Marrow Transplantation, Published online: 19 September 2019; doi:10.1038/s41409-019-0674-2Autologous hematopoietic stem cell infusion for sustained myelosuppression after BCMA–CAR-T therapy in patient with relapsed myeloma
Source: Bone Marrow Transplantation - Category: Hematology Authors: Source Type: research
More News: Brain | Genetics | Medical Ethics | Molecular Biology | Neurology | Stem Cell Therapy | Stem Cells | Study | Transplants